financetom
Business
financetom
/
Business
/
Update: BlackRock Q2 Adjusted Earnings, Revenue Rise; Assets Under Management Up 18%
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Update: BlackRock Q2 Adjusted Earnings, Revenue Rise; Assets Under Management Up 18%
Jul 15, 2025 5:19 AM

07:48 AM EDT, 07/15/2025 (MT Newswires) -- (Updates with assets under management data in headline and fifth paragraph; latest stock move in last paragraph.)

BlackRock ( BLK ) reported Q2 adjusted earnings Tuesday of $12.05 per diluted share, up from $10.36 a year earlier.

Analysts surveyed by FactSet expected $10.78.

Revenue for the three months ended June 30 was $5.42 billion, compared with $4.81 billion a year ago.

Analysts surveyed by FactSet expected $5.45 billion.

The company said its assets under management reached $12.528 trillion, about 18% higher than $10.646 trillion a year earlier.

The company's shares were down 1.8% in recent premarket activity Tuesday.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
What's Going On With ASP Isotopes Stock Monday?
What's Going On With ASP Isotopes Stock Monday?
Dec 16, 2024
ASP Isotopes Inc ( ASPI ) shares are trading higher. The company on Monday wrote a letter to shareholders, providing a balance sheet update, highlighting progress on goals and announcing an investor access event. What Happened: ASP Isotopes ( ASPI ) chairman and CEO Paul Mann highlighted several milestones for 2024 and set the stage for 2025 in a letter...
Sinovac Biotech Starts Enrolment in Late-Stage Trial of Investigational Bivalent Vaccine for HFMD
Sinovac Biotech Starts Enrolment in Late-Stage Trial of Investigational Bivalent Vaccine for HFMD
Dec 16, 2024
09:21 AM EST, 12/16/2024 (MT Newswires) -- Sinovac Biotech ( SVA ) said Monday that it has begun enrollment in a late-stage study of its investigational bivalent vaccine targeting Hand, Foot, and Mouth Disease, or HFMD, caused by enterovirus 71 and coxsackievirus 16. The company said the trial will evaluate the potential vaccine's efficacy, safety, and immune response in children...
Shyft to Merge With Aebi Schmidt in All-Stock Deal
Shyft to Merge With Aebi Schmidt in All-Stock Deal
Dec 16, 2024
09:25 AM EST, 12/16/2024 (MT Newswires) -- Shyft ( SHYF ) and Aebi Schmidt said Monday they have agreed to merge in an all-stock deal to create a specialty vehicles company. Under the deal, each outstanding Shyft ( SHYF ) share will be exchanged for 1.04 shares of the combined company's shares, the companies said, adding that Shyft ( SHYF...
Corcept Therapeutics' Phase 3 Study of Relacorilant Shows Improvements in Patients With Hypercortisolism
Corcept Therapeutics' Phase 3 Study of Relacorilant Shows Improvements in Patients With Hypercortisolism
Dec 16, 2024
09:29 AM EST, 12/16/2024 (MT Newswires) -- Corcept Therapeutics ( CORT ) said Monday that results from its phase 3 study of relacorilant to treat patients suffering from endogenous hypercortisolism showed clinically meaningful and durable cardiometabolic improvements. Hypercortisolism, or Cushing's syndrome, occurs when the body produces too much cortisol, which can cause high blood pressure leading to increased cardiovascular risk...
Copyright 2023-2026 - www.financetom.com All Rights Reserved